MiMedx Q1 FY26 net loss widens to $11 million; net sales fall 33% to $59 million

• MiMedx posted a first-quarter net loss of $11 million, swinging from profit a year earlier.
• Net sales fell 33% to $59 million.
• Adjusted EBITDA deteriorated to a loss of $11.56 million from a gain a year earlier, reflecting disruption from new Medicare reimbursement policies in advanced wound care.
• Surgical sales increased 13% to $36.37 million, while Wound sales plunged 60% to $22.62 million; management cited confusion and inconsistent implementation by Medicare Administrative Contractors.
• MiMedx cut 2026 net sales outlook to $260 million-$290 million, while forecasting full-year adjusted EBITDA of about breakeven.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MiMedx Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604291601PRIMZONEFULLFEED9709819) on April 29, 2026, and is solely responsible for the information contained therein.